4-((4-(4-Chloro-3-(trifluoromethyl)phenoxy)-3,5-difluorobenzyl)-oxy)-1-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-2(1H)-one

ID: ALA3792672

Chembl Id: CHEMBL3792672

PubChem CID: 121448431

Max Phase: Preclinical

Molecular Formula: C24H22ClF5N4O3

Molecular Weight: 544.91

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CN1CCN(c2cc(OCc3cc(F)c(Oc4ccc(Cl)c(C(F)(F)F)c4)c(F)c3)nc(=O)n2C)CC1

Standard InChI:  InChI=1S/C24H22ClF5N4O3/c1-32-5-7-34(8-6-32)21-12-20(31-23(35)33(21)2)36-13-14-9-18(26)22(19(27)10-14)37-15-3-4-17(25)16(11-15)24(28,29)30/h3-4,9-12H,5-8,13H2,1-2H3

Standard InChI Key:  FFUJWARHMSHZEP-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3792672

    ---

Associated Targets(Human)

PLA2G7 Tchem LDL-associated phospholipase A2 (1338 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver (3974 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Liver (4264 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 544.91Molecular Weight (Monoisotopic): 544.1301AlogP: 4.85#Rotatable Bonds: 6
Polar Surface Area: 59.83Molecular Species: NEUTRALHBA: 7HBD: 0
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 0#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 7.39CX LogP: 5.00CX LogD: 4.71
Aromatic Rings: 3Heavy Atoms: 37QED Weighted: 0.41Np Likeness Score: -1.22

References

1. Chen X, Wang K, Xu W, Ma Q, Chen M, Du L, Mo M, Wang Y, Shen J..  (2016)  Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.,  59  (6): [PMID:26927682] [10.1021/acs.jmedchem.5b01930]

Source